KYTX (Kyverna Therapeutics) Notes Receivable: $0.00 Mil (As of Mar. 2026)


KYTX Kyverna Therapeutics Inc KYTX
12 GF Score
Price $8.88
! 1 Warning Sign
View Full Analysis

What is Kyverna Therapeutics Notes Receivable?

Kyverna Therapeutics KYTX +5.21% 12 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates KYTX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Kyverna Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Kyverna Therapeutics Notes Receivable Related Terms

Kyverna Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Kyverna Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyverna Therapeutics Notes Receivable Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00 0.00

Kyverna Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KYTX
12GF Score
Kyverna Therapeutics Inc KYTX
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyverna Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Kyverna Therapeutics (KYTX) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Kyverna Therapeutics and its competitors.
Is Kyverna Therapeutics' Notes Receivable too high?
Kyverna Therapeutics' current Notes Receivable is $0.00 Mil. Overall, Kyverna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kyverna Therapeutics' Notes Receivable compare to ZURA and CBIO?
Kyverna Therapeutics' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Kyverna Therapeutics and its competitors. Kyverna Therapeutics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyverna Therapeutics stock overvalued right now?
Kyverna Therapeutics (KYTX) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Kyverna Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Kyverna Therapeutics (KYTX), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kyverna Therapeutics Business Description

Address 5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
12GF Score

Get the complete analysis for KYTX

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.88
Price